Alternatives to Lactulose for Hepatic Encephalopathy

First-Line Alternative: Rifaximin

The American Association for the Study of Liver Diseases recommends rifaximin 550 mg twice daily as the primary alternative to lactulose for hepatic encephalopathy, though it is most effective when added to lactulose rather than used alone 1, 2
Rifaximin monotherapy lacks robust placebo-controlled data without concurrent lactulose use, making it difficult to recommend as sole therapy, with a strength of evidence based on expert opinion rather than high-quality evidence 1, 2

Neomycin 1-2 grams orally 2-4 times daily is an alternative antibiotic option when both lactulose and rifaximin cannot be used, according to the Hepatology society 3, 5
The European Association for the Study of the Liver warns that long-term use of neomycin carries significant risks of ototoxicity, nephrotoxicity, and neurotoxicity, making it unsuitable for continuous therapy, with regular monitoring of renal function essential 3, 5
Metronidazole can be used for short-term therapy of overt hepatic encephalopathy, with a Grade II-3, B, 2 recommendation from the Hepatology society, though the same toxicity concerns as neomycin limit long-term use 3, 5

Intravenous L-Ornithine L-Aspartate (LOLA) can be used as an alternative or additional agent in patients nonresponsive to conventional therapy, with a Grade I, B, 2 recommendation from the Hepatology society 3, 4
Oral Branched-Chain Amino Acids (BCAAs) can serve as an alternative or additional agent for patients nonresponsive to conventional therapy, with a Grade I, B, 2 recommendation from the Hepatology society, and have shown particular benefit in minimal hepatic encephalopathy 3, 6
Lactitol is another non-absorbable disaccharide that can be substituted for lactulose with similar efficacy, according to the Journal of Hepatology 1, 5

The treatment algorithm recommends rifaximin 550 mg twice daily as monotherapy as the first choice 1, 2
If rifaximin is unavailable or contraindicated, neomycin with close renal monitoring is recommended 3, 4
For acute episodes, consider IV LOLA as adjunctive therapy 3, 4
For chronic management, consider adding oral BCAAs 3

The Journal of Hepatology warns against using simple laxatives alone, as they lack the prebiotic properties of disaccharides and are ineffective 5, 6
Overuse of any laxative can lead to dehydration, hypernatremia, aspiration risk, and paradoxically worsen hepatic encephalopathy, according to the Journal of Hepatology 5
Always identify and treat precipitating factors first, as nearly 90% of patients can be managed by correcting precipitating factors alone, such as infection, GI bleeding, electrolyte disturbances, and constipation 5, 7

For post-TIPS hepatic encephalopathy, neither rifaximin nor lactulose has been shown to prevent episodes better than placebo, so routine prophylaxis is not recommended, according to the Hepatology society 3, 6
Therapeutic education programs for patients and caregivers should be offered to improve quality of life and reduce hospitalizations, as 22% of readmissions are preventable with proper medication management, recommended by the Liver International society 1